Zuoli Pharmaceutical: Shenling Granules received the drug clinical trial approval notice.

Sali Pharmaceutical announced that its self-developed Chinese medicine, Class 1.1 new drug Canling Granules, has recently received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, allowing for clinical trials for the treatment of functional digestive disorders caused by spleen deficiency and qi stagnation. Canling Granules, as an innovative drug in the Wuling series, is formulated based on Wuling mushroom powder and traditional clinical experience of famous doctors, and is intended for the treatment of this syndrome. The company stated that the process from clinical trials to market launch is long and risky, and the approval of this trial will not have a significant impact on the company's performance, and there is uncertainty regarding the progress and results of the subsequent clinical trials.